Developer docs
API playgroundTry for free, no card

Search company profiles

Pattern Computer

Full company profile

uuid0000d9g

Namestring
Pattern Computer
Legal namestring
Pattern Computer, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Pattern Computer, Inc. is a private AI platform company founded in 2016 and headquartered in Redmond, WA, with an additional Pattern Discovery Mathematics Center in San Diego, CA. The company has built its business around the proprietary Pattern Discovery Engine (PDE), a domain-agnostic, explainable AI system that uses novel mathematical techniques to reveal hidden relationships in complex, high-dimensional data that conventional neural networks and LLMs miss. Around the PDE core, Pattern Computer has assembled a portfolio of specialized products: ProSpectral (hyperspectral, reagent-free multi-disease diagnostics with EMC certification and 98.5% balanced COVID detection performance), PatternDE (the first online Pattern Discovery Engine for tabular data launched in January 2025), TrueXAI (decision-function extraction from neural networks), RC/XAI (risk-aware XAI for financial markets launched in 2025), AES (Adaptive Example Selection, peer-reviewed in Nature: Scientific Reports at 96% fidelity), and the investigational cancer therapy PCI020302 for triple-negative breast cancer, which holds global patent protection through 2040. The oncology pipeline also includes candidates for high-grade serous ovarian cancer (31 combination candidates identified computationally in 6 weeks), colorectal cancer (in collaboration with Fred Hutch and GECCO), glioblastoma, hepatocellular carcinoma, and metastatic castration-resistant prostate cancer.

Pattern Computer generates revenue through three primary streams: drug discovery and development licensing (anchored by PCI020302 and other oncology candidates), AI platform and technology licensing of the PDE to enterprise customers across biotech, finance, aerospace, veterinary, energy, and government research sectors, and commercialization of the ProSpectral diagnostics hardware. The PatternDE online platform introduces a subscription/usage-based self-serve component alongside the direct enterprise sales motion. Customer and partner evidence is concentrated in research collaborations rather than disclosed commercial accounts: named partners include Fred Hutch Cancer Research Center, University of Washington, Medical College of Wisconsin, Phenome Health, UCSD/Calit2, the J. Craig Venter Institute, and Scripps Research Institutes. The company has raised roughly $26.1M in disclosed funding (most recently in February 2022), operates with 11-50 employees, and has not announced institutional funding since, suggesting capital efficiency or founder/bootstrapped ownership. Distribution is dominated by direct enterprise engagement, conference-based business development (FiRe, BIO-Europe, J.P. Morgan Healthcare Conference, Life Science Innovation Northwest, AI.SUMMIT Hamburg), and scientific publications as thought leadership.

Short descriptiontext

Pattern Computer is a private AI platform company that has built the proprietary Pattern Discovery Engine (PDE) to uncover hidden patterns in high-dimensional data, serving biotech, pharmaceutical, healthcare, and enterprise customers through drug licensing, AI platform licensing, and hyperspectral diagnostics products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedmond, United States
HQ citystring
Redmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pattern discovery software, explainable AI platform, AI drug discovery, hyperspectral diagnostics, high-dimensional data analytics
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Software Publishers5132
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI-Powered Pattern Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Discovery & Development Licensing
TypeLicensing Royalties
Description

Pattern Computer generates revenue through licensing its AI-discovered drug candidates to pharmaceutical partners, as well as advancing its own pipeline toward clinical development and commercialization. The company's PCI020302 triple-negative breast cancer therapy has an IP portfolio extending market exclusivity through 2040 across multiple geographies.

patterncomputer.com
2AI Platform & Technology Licensing
TypeSubscription Recurring
Description

The company licenses its Pattern Discovery Engine technology to enterprise customers across multiple sectors including biotech, diagnostics, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, energy services, and finance. The online PatternDE platform enables subscription-based or usage-based access to pattern discovery capabilities.

patterncomputer.com
3ProSpectral Diagnostics Platform
TypeHardware Sales
Description

ProSpectral multi-disease hyperspectral diagnostics research platform is available for commercial deployment. The platform has passed EMC certifications required for commercial sales, enabling broad multi-disease screening applications.

patterncomputer.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1Pattern Discovery Engine (PDE)
Description

Proprietary AI platform for finding complex patterns in high-dimensional data

patterncomputer.com
+7 more records
Core offering1 text field

Pattern Computer develops and commercializes its proprietary Pattern Discovery Engine (PDE), an AI platform that uses novel mathematical techniques to find previously hidden, complex patterns in very-high-dimensional tabular data. The platform is domain-agnostic and produces explainable, hallucination-free insights applied across oncology drug discovery, hyperspectral multi-disease diagnostics (ProSpectral), risk-aware financial AI (RC/XAI), and fundamental physics research (Resonance Theory).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 96% fidelity between AI predictions and explanations in digital pathology (mitosis detection)
+4 more records
Product overview1 text field

Pattern Computer is a next-generation AI platform company that has developed a unified portfolio built around its proprietary Pattern Discovery Engine (PDE). The core offering is the Pattern Discovery Engine, which serves as the foundational platform for multiple specialized products and applications. The product suite includes ProSpectral for multi-disease diagnostics, PatternDE for online tabular data analysis, and PatternBio for drug discovery. Supporting these core offerings are TrueXAI and RC/XAI for explainable AI capabilities, AES (Adaptive Example Selection) for medical AI interpretability, and the PCI020302 investigational cancer therapy developed through AI-driven drug discovery. The company also maintains a Pattern Discovery Mathematics Center in San Diego for collaborative research. This platform-plus-modules architecture enables Pattern Computer to address applications across biotech, diagnostics, financial markets, and advanced AI research.

Product and service7 records
1Pattern Discovery Engine (PDE)
CategoryCore AI Platform
Description

Proprietary AI platform using breakthrough pattern discovery algorithms to reveal previously hidden relationships in complex, high-dimensional data. Domain-agnostic, explainable, and capable of generating transparent, biologically validated insights for enterprise customers across biotech, finance, aerospace, and other sectors.

2PatternDE (Online Pattern Discovery Engine)
CategoryOnline Analytics Platform
Description

The first commercial online Pattern Discovery Engine for transforming investigation, analysis, and modeling of high-dimensional tabular data into an intuitive and transparent process at scale, accessible via online subscription/usage-based access.

3ProSpectral
CategoryDiagnostic Hardware & Software Platform
Description

Fast, accurate, multi-disease hyperspectral diagnostics platform that uses light-based spectral analysis for reagent-free, chemical-free disease screening. Delivers 98.5% balanced performance for COVID detection in 3-10 seconds. EMC certified for commercial sales.

4TrueXAI
CategoryExplainable AI Platform
Description

Explainable AI platform that derives previously hidden local manifolds from neural network models (including deep neural nets), extracting actual decision functions to turn neural networks from black boxes into glass boxes for full transparency of AI decision-making.

5RC/XAI (Risk and Confidence XAI)
CategoryRisk-Aware AI Platform
Description

Next-generation risk-aware explainable AI tool for mission-critical applications, advancing trust and transparency in high-stakes decision making for financial markets and other regulated industries where risk and confidence quantification are essential.

6Adaptive Example Selection (AES) Framework
CategoryMedical AI Interpretability Framework
Description

Framework for medical AI interpretability that uses adaptive, contrastive example selection presenting both supporting and opposing evidence for each AI decision. Achieves 96% fidelity between predictions and explanations, validated in digital pathology for mitosis detection.

7PCI020302 (Triple-Negative Breast Cancer Therapy)
CategoryPharmaceutical Drug Candidate
Description

Investigational AI-discovered novel combination therapy for triple-negative breast cancer (TNBC), an aggressive cancer subtype with limited treatment options. Available for licensing to pharmaceutical partners with global patent protection through 2040.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-06
Description

Pattern Computer announced a partnership with Phenome Health in December 2024, deploying the Pattern Discovery Engine and ProSpectral platform to discover new drivers of human health. This partnership aligns with Pattern's expansion into broader health and wellness applications beyond oncology, leveraging hyperspectral diagnostics and pattern discovery for predictive health insights.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Pattern and the Medical College of Wisconsin launched a pilot study in August 2024 to assess detection of head, neck, and lung cancers through ProSpectral saliva analysis. This research collaboration aims to enable a new era of early detection cancer screening using Pattern's multi-disease hyperspectral diagnostics platform.

3UCSD (University of California San Diego)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-20
Description

Pattern Computer established a Pattern Discovery Mathematics Center in San Diego in December 2021, anchored by a special agreement with the UCSD Regents on IP protection and sharing. The company has ongoing working relationships with UCSD's Dr. Larry Smarr, Professor Emeritus, and Chancellor Pradeep Khosla. UCSD's Calit2 (California Institute of Telecommunications and Information Technology) is part of the alliance structure.

patterncomputer.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-20
Description

Pattern Computer has established an alliance with the J. Craig Venter Institute as part of its expanded connections in the San Diego region, supporting the company's biotech and genomics-focused research initiatives.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-20
Description

Pattern Computer has working relationships with the Scripps Research Institutes as part of its San Diego-based alliance structure supporting life sciences and biomedical research collaborations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pattern Computer works with the Fred Hutch Cancer Research Center to obtain sufficient data on metastatic castration-resistant prostate cancer for Pattern Discovery Engine analysis. The partnership also provided data from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) for colorectal cancer drug target discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pattern Computer collaborated with University of Washington researchers to discover that the development of subepithelial infiltrates (SEI) due to conjunctivitis infection can be accurately predicted from knowledge of the full viral sequence. This research was published in Ophthalmology Science.

8National Clinical Testing Organization
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Pattern Computer's ovarian cancer and other preclinical drug testing is conducted at a nationally-recognized clinical testing organization, engaging external laboratory services for in vitro and in vivo validation of AI-discovered drug candidates.

patterncomputer.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI drug discovery company using structure-based deep learning to identify small molecule therapeutics. Comparable in using proprietary AI methods to discover drug candidates for hard-to-treat diseases.

TypeDirect peer
Description

AI-driven drug discovery and aging research company with end-to-end pipeline from target identification through clinical development. Comparable in applying AI to identify novel drug targets and candidates across multiple therapeutic areas.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining high-throughput biology data with ML models. Directly comparable as an AI-native drug discovery company using data-driven approaches to identify novel therapeutics.

TypeDirect peer
Description

AI-powered drug discovery company combining physics, chemistry, and machine learning for molecular design. Comparable in offering AI-based discovery platforms that identify novel drug candidates and accelerate development timelines.

TypeDirect peer
Description

Computational chemistry and drug discovery platform combining physics-based modeling with machine learning. Comparable to Pattern's PDE for discovering drug candidates and therapeutic combinations through computational methods.

TypeBroad incumbent
Description

Enterprise AI platform company providing machine learning and explainable AI tools for data analysis across industries. Comparable in offering AI-based pattern discovery and interpretability capabilities as an enterprise platform.

TypeDirect peer
Description

AI-driven drug discovery company using high-dimensional biology data and machine learning to identify novel therapeutics. Directly comparable as a computational drug discovery platform pursuing AI-discovered drug candidates through preclinical and clinical development.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Comparable in applying AI to discover patterns in biomedical data and identify therapeutic candidates.

TypeDirect peer
Description

AI-driven precision medicine company using its AI platform to accelerate small molecule drug discovery. Comparable to Pattern's PatternBio in applying AI to identify drug candidates and combinations.

10Tempus Labs
TypeBroad incumbent
Description

AI-driven precision medicine company combining large-scale data analytics with healthcare applications. Comparable in applying AI to healthcare data for oncology and other therapeutic areas, with a broader portfolio than Pattern's drug discovery focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pattern Computer

AI-Powered Pattern Discovery Platformpatterncomputer.com

Pattern Computer is a private AI platform company that has built the proprietary Pattern Discovery Engine (PDE) to uncover hidden patterns in high-dimensional data, serving biotech, pharmaceutical, healthcare, and enterprise customers through drug licensing, AI platform licensing, and hyperspectral diagnostics products.

What Pattern Computer does

Pattern Computer, Inc. is a private AI platform company founded in 2016 and headquartered in Redmond, WA, with an additional Pattern Discovery Mathematics Center in San Diego, CA. The company has built its business around the proprietary Pattern Discovery Engine (PDE), a domain-agnostic, explainable AI system that uses novel mathematical techniques to reveal hidden relationships in complex, high-dimensional data that conventional neural networks and LLMs miss. Around the PDE core, Pattern Computer has assembled a portfolio of specialized products: ProSpectral (hyperspectral, reagent-free multi-disease diagnostics with EMC certification and 98.5% balanced COVID detection performance), PatternDE (the first online Pattern Discovery Engine for tabular data launched in January 2025), TrueXAI (decision-function extraction from neural networks), RC/XAI (risk-aware XAI for financial markets launched in 2025), AES (Adaptive Example Selection, peer-reviewed in Nature: Scientific Reports at 96% fidelity), and the investigational cancer therapy PCI020302 for triple-negative breast cancer, which holds global patent protection through 2040. The oncology pipeline also includes candidates for high-grade serous ovarian cancer (31 combination candidates identified computationally in 6 weeks), colorectal cancer (in collaboration with Fred Hutch and GECCO), glioblastoma, hepatocellular carcinoma, and metastatic castration-resistant prostate cancer.

Pattern Computer generates revenue through three primary streams: drug discovery and development licensing (anchored by PCI020302 and other oncology candidates), AI platform and technology licensing of the PDE to enterprise customers across biotech, finance, aerospace, veterinary, energy, and government research sectors, and commercialization of the ProSpectral diagnostics hardware. The PatternDE online platform introduces a subscription/usage-based self-serve component alongside the direct enterprise sales motion. Customer and partner evidence is concentrated in research collaborations rather than disclosed commercial accounts: named partners include Fred Hutch Cancer Research Center, University of Washington, Medical College of Wisconsin, Phenome Health, UCSD/Calit2, the J. Craig Venter Institute, and Scripps Research Institutes. The company has raised roughly $26.1M in disclosed funding (most recently in February 2022), operates with 11-50 employees, and has not announced institutional funding since, suggesting capital efficiency or founder/bootstrapped ownership. Distribution is dominated by direct enterprise engagement, conference-based business development (FiRe, BIO-Europe, J.P. Morgan Healthcare Conference, Life Science Innovation Northwest, AI.SUMMIT Hamburg), and scientific publications as thought leadership.

Pattern Computer firmographics

Firmographics
Name
Pattern Computer
Legal name
Pattern Computer, Inc.
Website
https://patterncomputer.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Pattern Computer is a private AI platform company that has built the proprietary Pattern Discovery Engine (PDE) to uncover hidden patterns in high-dimensional data, serving biotech, pharmaceutical, healthcare, and enterprise customers through drug licensing, AI platform licensing, and hyperspectral diagnostics products.
Ownership category
akta.pro rank

Pattern Computer industry classification

Industry
Product category
AI-Powered Pattern Discovery Platform
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Software Publishers (5132)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Pattern discovery software
  • Explainable AI platform
  • AI drug discovery
  • Hyperspectral diagnostics
  • High-dimensional data analytics

Where Pattern Computer is headquartered

Location

Headquarters

HQ city
Redmond
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pattern Computer business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Drug Discovery & Development Licensing: Pattern Computer generates revenue through licensing its AI-discovered drug candidates to pharmaceutical partners, as well as advancing its own pipeline toward clinical development and commercialization. The company's PCI020302 triple-negative breast cancer therapy has an IP portfolio extending market exclusivity through 2040 across multiple geographies.
  2. AI Platform & Technology Licensing: The company licenses its Pattern Discovery Engine technology to enterprise customers across multiple sectors including biotech, diagnostics, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, energy services, and finance. The online PatternDE platform enables subscription-based or usage-based access to pattern discovery capabilities.
  3. ProSpectral Diagnostics Platform: ProSpectral multi-disease hyperspectral diagnostics research platform is available for commercial deployment. The platform has passed EMC certifications required for commercial sales, enabling broad multi-disease screening applications.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Pattern Computer product offering

Product offering

Core offering

Pattern Computer develops and commercializes its proprietary Pattern Discovery Engine (PDE), an AI platform that uses novel mathematical techniques to find previously hidden, complex patterns in very-high-dimensional tabular data. The platform is domain-agnostic and produces explainable, hallucination-free insights applied across oncology drug discovery, hyperspectral multi-disease diagnostics (ProSpectral), risk-aware financial AI (RC/XAI), and fundamental physics research (Resonance Theory).

Product overview

Pattern Computer is a next-generation AI platform company that has developed a unified portfolio built around its proprietary Pattern Discovery Engine (PDE). The core offering is the Pattern Discovery Engine, which serves as the foundational platform for multiple specialized products and applications. The product suite includes ProSpectral for multi-disease diagnostics, PatternDE for online tabular data analysis, and PatternBio for drug discovery. Supporting these core offerings are TrueXAI and RC/XAI for explainable AI capabilities, AES (Adaptive Example Selection) for medical AI interpretability, and the PCI020302 investigational cancer therapy developed through AI-driven drug discovery. The company also maintains a Pattern Discovery Mathematics Center in San Diego for collaborative research. This platform-plus-modules architecture enables Pattern Computer to address applications across biotech, diagnostics, financial markets, and advanced AI research.

Differentiator

Problem solved

Functional benefit

Brands

  • Pattern Discovery Engine (PDE): Proprietary AI platform for finding complex patterns in high-dimensional data
  • PatternDE
  • ProSpectral
  • PatternBio
  • TrueXAI
  • RC/XAI
  • AES (Adaptive Example Selection)
  • ProSpectral

Products and services

  • Pattern Discovery Engine (PDE) Proprietary AI platform using breakthrough pattern discovery algorithms to reveal previously hidden relationships in complex, high-dimensional data. Domain-agnostic, explainable, and capable of generating transparent, biologically validated insights for enterprise customers across biotech, finance, aerospace, and other sectors.
  • PatternDE (Online Pattern Discovery Engine) The first commercial online Pattern Discovery Engine for transforming investigation, analysis, and modeling of high-dimensional tabular data into an intuitive and transparent process at scale, accessible via online subscription/usage-based access.
  • ProSpectral Fast, accurate, multi-disease hyperspectral diagnostics platform that uses light-based spectral analysis for reagent-free, chemical-free disease screening. Delivers 98.5% balanced performance for COVID detection in 3-10 seconds. EMC certified for commercial sales.
  • TrueXAI Explainable AI platform that derives previously hidden local manifolds from neural network models (including deep neural nets), extracting actual decision functions to turn neural networks from black boxes into glass boxes for full transparency of AI decision-making.
  • RC/XAI (Risk and Confidence XAI) Next-generation risk-aware explainable AI tool for mission-critical applications, advancing trust and transparency in high-stakes decision making for financial markets and other regulated industries where risk and confidence quantification are essential.
  • Adaptive Example Selection (AES) Framework Framework for medical AI interpretability that uses adaptive, contrastive example selection presenting both supporting and opposing evidence for each AI decision. Achieves 96% fidelity between predictions and explanations, validated in digital pathology for mitosis detection.
  • PCI020302 (Triple-Negative Breast Cancer Therapy) Investigational AI-discovered novel combination therapy for triple-negative breast cancer (TNBC), an aggressive cancer subtype with limited treatment options. Available for licensing to pharmaceutical partners with global patent protection through 2040.

Quantifiable outcome

  • 96% fidelity between AI predictions and explanations in digital pathology (mitosis detection)
  • +4 more outcomes

Companies that use Pattern Computer

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Pattern Computer technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Pattern Computer partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Phenome HealthcoreStrategic or Co-development Partner · 6 December 2024Pattern Computer announced a partnership with Phenome Health in December 2024, deploying the Pattern Discovery Engine and ProSpectral platform to discover new drivers of human health. This partnership aligns with Pattern's expansion into broader health and wellness applications beyond oncology, leveraging hyperspectral diagnostics and pattern discovery for predictive health insights.
  • Medical College of WisconsinminorStrategic or Co-development Partner · 21 August 2024Pattern and the Medical College of Wisconsin launched a pilot study in August 2024 to assess detection of head, neck, and lung cancers through ProSpectral saliva analysis. This research collaboration aims to enable a new era of early detection cancer screening using Pattern's multi-disease hyperspectral diagnostics platform.
  • UCSD (University of California San Diego)coreStrategic or Co-development Partner · 20 December 2021Pattern Computer established a Pattern Discovery Mathematics Center in San Diego in December 2021, anchored by a special agreement with the UCSD Regents on IP protection and sharing. The company has ongoing working relationships with UCSD's Dr. Larry Smarr, Professor Emeritus, and Chancellor Pradeep Khosla. UCSD's Calit2 (California Institute of Telecommunications and Information Technology) is part of the alliance structure.
  • J. Craig Venter InstituteminorStrategic or Co-development Partner · 20 December 2021Pattern Computer has established an alliance with the J. Craig Venter Institute as part of its expanded connections in the San Diego region, supporting the company's biotech and genomics-focused research initiatives.
  • Scripps Research InstitutesminorStrategic or Co-development Partner · 20 December 2021Pattern Computer has working relationships with the Scripps Research Institutes as part of its San Diego-based alliance structure supporting life sciences and biomedical research collaborations.
  • Fred Hutch Cancer Research CentercoreStrategic or Co-development PartnerPattern Computer works with the Fred Hutch Cancer Research Center to obtain sufficient data on metastatic castration-resistant prostate cancer for Pattern Discovery Engine analysis. The partnership also provided data from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) for colorectal cancer drug target discovery.
  • University of WashingtoncoreStrategic or Co-development PartnerPattern Computer collaborated with University of Washington researchers to discover that the development of subepithelial infiltrates (SEI) due to conjunctivitis infection can be accurately predicted from knowledge of the full viral sequence. This research was published in Ophthalmology Science.
  • National Clinical Testing OrganizationminorImplementation/ SI/ Consulting PartnerPattern Computer's ovarian cancer and other preclinical drug testing is conducted at a nationally-recognized clinical testing organization, engaging external laboratory services for in vitro and in vivo validation of AI-discovered drug candidates.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Pattern Computer competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI drug discovery company using structure-based deep learning to identify small molecule therapeutics. Comparable in using proprietary AI methods to discover drug candidates for hard-to-treat diseases.
  • InSilico Medicine: AI-driven drug discovery and aging research company with end-to-end pipeline from target identification through clinical development. Comparable in applying AI to identify novel drug targets and candidates across multiple therapeutic areas.
  • Insitro: Machine learning-driven drug discovery company combining high-throughput biology data with ML models. Directly comparable as an AI-native drug discovery company using data-driven approaches to identify novel therapeutics.
  • XtalPi: AI-powered drug discovery company combining physics, chemistry, and machine learning for molecular design. Comparable in offering AI-based discovery platforms that identify novel drug candidates and accelerate development timelines.
  • Schrödinger Inc. Computational chemistry and drug discovery platform combining physics-based modeling with machine learning. Comparable to Pattern's PDE for discovering drug candidates and therapeutic combinations through computational methods.
  • Recursion Pharmaceuticals: AI-driven drug discovery company using high-dimensional biology data and machine learning to identify novel therapeutics. Directly comparable as a computational drug discovery platform pursuing AI-discovered drug candidates through preclinical and clinical development.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Comparable in applying AI to discover patterns in biomedical data and identify therapeutic candidates.
  • Exscientia: AI-driven precision medicine company using its AI platform to accelerate small molecule drug discovery. Comparable to Pattern's PatternBio in applying AI to identify drug candidates and combinations.

Broad incumbents

  • H2O.ai: Enterprise AI platform company providing machine learning and explainable AI tools for data analysis across industries. Comparable in offering AI-based pattern discovery and interpretability capabilities as an enterprise platform.
  • Tempus Labs: AI-driven precision medicine company combining large-scale data analytics with healthcare applications. Comparable in applying AI to healthcare data for oncology and other therapeutic areas, with a broader portfolio than Pattern's drug discovery focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pattern Computer social profiles

Digital presence

Pattern Computer compliance and trust

Trust signal

Compliance1 record

Pattern Computer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pattern Computer leadership team

Management profile

Number of profiles

Profiles9 records

Pattern Computer funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pattern Computer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pattern Computer

What does Pattern Computer do?

Pattern Computer develops and commercializes its proprietary Pattern Discovery Engine (PDE), an AI platform that uses novel mathematical techniques to find previously hidden, complex patterns in very-high-dimensional tabular data. The platform is domain-agnostic and produces explainable, hallucination-free insights applied across oncology drug discovery, hyperspectral multi-disease diagnostics (ProSpectral), risk-aware financial AI (RC/XAI), and fundamental physics research (Resonance Theory).

Is Pattern Computer a public or private company?

Pattern Computer is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pattern Computer founded?

Pattern Computer was founded in 2016. It employs 11 to 50 people.

Where is Pattern Computer based?

Pattern Computer is headquartered in Redmond, United States, in the North America region.

How does Pattern Computer make money?

Three revenue lines are on record. Drug Discovery & Development Licensing is the primary driver. The others are AI Platform & Technology Licensing and proSpectral Diagnostics Platform.

Who are Pattern Computer's main competitors?

Direct peers on record are Atomwise, InSilico Medicine, Insitro, XtalPi, Schrödinger Inc., Recursion Pharmaceuticals, BenevolentAI and Exscientia. Broad incumbents are H2O.ai and Tempus Labs.

Does Pattern Computer have an API?

No public API is recorded for Pattern Computer.

What industry is Pattern Computer in?

Pattern Computer's product category is AI-Powered Pattern Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 54171 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPattern Computer To Participate In Goldman Sachs Private Innovative Company ConferencePattern Computer will participate in Goldman Sachs' private innovative company conference, where its CEO will meet with institutional investors. The company's Pattern Discovery Engine claims to provide transparent, hallucination-free AI insights across sectors like biotech and energy. The company also highlights its domain-agnostic platform for drug discovery and diagnostics.YahooPattern Computer Appoints Former MI6 Chief Sir Richard B. Dearlove to Advisory BoardPattern Computer, Inc. has appointed former MI6 Chief Sir Richard B. Dearlove to its Advisory Board effective immediately. In this role, Sir Richard will provide strategic counsel on global expansion and help enhance the company's AI safety and risk-assessment frameworks.GlobeNewswirePattern to Host Advanced AI Day at FiRe 2026 ConferencePattern Computer, Inc. announced it will host Advanced AI Day at the 22nd Annual Future in Review Conference (FiRe 2026) scheduled for May 31 – June 3, 2026, at the Qualcomm Institute at UC San Diego. The conference, dubbed 'the best technology conference in the world' by The Economist, brings together global leaders in advanced AI, climate tech, semiconductors, and other technology sectors. Pattern's CEO Mark R. Anderson highlighted the company's Pattern Discovery Engine technology, positioning it as a hallucination-free, explainable AI approach that differs from conventional neural network methods.GlobeNewswirePattern to Host Advanced AI Day at FiRe 2026 ConferencePattern Computer will host the Advanced AI Day at FiRe 2026, held May 31–June 3, 2026 at UC San Diego. The event features five new physics papers and a reception, with themes including advanced learning AI, global security, and climate tech. Pattern's Pattern Discovery Engine is highlighted as a new approach to explainable AI.GlobeNewswirePattern to Present at Life Science Innovation Northwest 2026Pattern Computer, Inc. announced that its Chair and CEO Mark Anderson will present at Life Science Innovation Northwest 2026 on April 22, focusing on the company's Pattern Discovery Engine (PDE) technology for bio research teams. The conference, held at the Seattle Convention Center on April 21-22, is described as the Pacific Northwest's premier life science event bringing together CEOs, investors, research institutions, and life science organizations. Anderson's presentation will highlight the PDE platform's ability to uncover previously hidden patterns in complex data for drug discovery and diagnostics applications.GlobeNewswirePattern Publishes Breakthrough Explainable AI Framework in Scientific Reports, Advancing Trust and Adoption in High-Stakes IndustriesPattern Computer, Inc. announced the publication of its explainable AI (XAI) framework research in Nature: Scientific Reports, introducing a novel approach that makes AI decisions both accurate and interpretable for regulated industries. The framework, validated in digital pathology for mitosis detection, achieves 96% fidelity between predictions and explanations by using adaptive, contrastive example selection that presents both supporting and opposing evidence for each decision. The company positions this advancement as enabling broader AI adoption in medical imaging, drug discovery, manufacturing quality control, and digital forensics, with plans to scale the framework to larger datasets and integrate it into real-time workflows.GlobeNewswirePattern Discovers New microRNA Drug for Treatment of Glioblastoma CancerPattern Computer, Inc. announced the discovery of a new microRNA (miRNA) drug with potential to inhibit tumor-promoting genes in Glioblastoma, leveraging the Company's Pattern Discovery Engine™ (PDE) technology. Testing protocols for the drug, named Euclid, are currently under evaluation, with analysis of The Cancer Genome Atlas data showing high expression of the target miRNA in approximately 75% of Glioblastoma patients. The Company is seeking partnership opportunities to advance its cancer drug discoveries into clinical trials for the world's top five cancers.The Manila TimesPattern Chair and CEO Mark R. Anderson to Participate in Pitchforce JPM Investment SummitPattern Computer, Inc. announced that its Chair and CEO, Mark R. Anderson, will participate in the Pitchforce Investment Summit in San Francisco on January 14, 2026, where the panel will discuss AI in Life Science. The company emphasizes its proprietary PatternDE AI platform and its role in advancing transparency and explainability in AI, as well as its applications across biotech, diagnostics, and other industries.GlobeNewswirePattern CEO Mark R. Anderson to Deliver Keynote Speech at Hamburg-based AI.SUMMIT 2025Pattern Computer, Inc. announced that its Chair and CEO Mark R. Anderson will deliver a keynote speech titled "The Future of AI" at the AI.SUMMIT 2025 conference on October 21, 2025, in Hamburg, Germany. Anderson plans to discuss his views on artificial general intelligence and present Pattern's proprietary PatternDE AI platform, which uses proprietary pattern discovery algorithms for data analysis. The conference, expected to draw 450 participants across four stages, focuses on applied AI and real-world AI applications across industries.GlobeNewswirePattern Computer Strengthens Global IP Portfolio for AI-Discovered Cancer Therapy PCI020302Pattern Computer, Inc. announced a significant expansion of its international intellectual property portfolio for investigational oncology candidate PCI020302, a combination therapy in development for Triple-Negative Breast Cancer, with patent grants in India and China and notices of allowance issued in Mexico, Europe, and the United States. The global patent protection could extend market exclusivity for PCI020302 through 2040. The milestones underscore the capabilities of Pattern's proprietary PatternDE™ AI platform in identifying novel therapeutic candidates through pattern discovery algorithms.